Sanofi caps insulin cost at $35 for uninsured US patients

Sanofi logo at the company’s headquarters during the annual earnings news conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier

Join now for FREE unlimited access to Reuters.com

Register

(Reuters) – French drugmaker Sanofi said on Wednesday that uninsured diabetes patients in the United States would pay no more than $35 for a 30-day supply of insulin, following heightened public scrutiny of the skyrocketing prices of the drug that saves lives.

Sanofi said the new price, down from the previous price of $99, will be effective from July 1.

US lawmakers have shut down healthcare companies over rising insulin costs, and the US House of Representatives passed a bill in March capping monthly insulin costs at $35. for people with health insurance.

Join now for FREE unlimited access to Reuters.com

Register

According to a 2020 Commonwealth Fund study, around two-thirds of uninsured insulin users aged 18 to 64 paid the full price – an average of $900 per month – for the lifesaving drug.

Sanofi with Eli Lilly and Co and Novo Nordisk represent 90% of the US insulin market. In 2020, Lilly announced a new co-pay system that covers most of its insulin products, capping the cost of insulin at $35 per month.

About 37.3 million Americans, or 11.3% of the population, have diabetes, according to the American Diabetes Association.

Join now for FREE unlimited access to Reuters.com

Register

Our standards: The Thomson Reuters Trust Principles.

Comments are closed.